A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Doi, Yohei; Hibino, Masaya; Hase, Ryota; Yamamoto, Michiko; Kasamatsu, Yu; Hirose, Masahiro; Mutoh, Yoshikazu; Homma, Yoshito; Terada, Masaki; Ogawa, Taku; Kashizaki, Fumihiro; Yokoyama, Toshihiko; Koba, Hayato; Kasahara, Hideki; Yokota, Kazuhisa; Kato, Hideaki; Yoshida, Junichi; Kita, Toshiyuki; Kato, Yasuyuki; Kamio, Tadashi; Kodama, Nobuhiro; Uchida, Yujiro; Ikeda, Nobuhiro; Shinoda, Masahiro; Nakagawa, Atsushi; Nakatsumi, Hiroki; Horiguchi, Tomoya; Iwata, Mitsunaga; Matsuyama, Akifumi; Banno, Sumi; Koseki, Takenao; Teramachi, Mayumi; Miyata, Masami; Tajima, Shigeru; Maeki, Takahiro; Nakayama, Eri; Taniguchi, Satoshi; Lim, Chang‐Kweng; Saijo, Masayuki; Imai, Takumi; Yoshida, Hisako; Kabata, Daijiro; Shintani, Ayumi; Yuzawa, Yukio; Kondo, Masashi

doi:10.1128/aac.01897-20

Public

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Published in Antimicrobial Agents and Chemotherapy • Sep 22, 2020

Authors:

Yohei Doi

Masaya Hibino

Ryota Hase

Abstract

Favipiravir is an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase that is approved for treatment of influenza in Japan. We conducted a prospective, randomized, open-label, multicenter trial of favipiravir for the treatment of COVID-19 at 25 hospitals across Japan. Eligible patien...

Subject

Favipiravir

Medicine

Regimen

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!